Kardiotoxická liečba v onkohematológii.

Chemotherapy and targeted therapy have significantly improved the prognosis of oncohaematological patients. Antineoplastic treatment can cause adverse cardiovascular effects known as cardiotoxicity, which requires modification, interruption or withdrawal of life-saving drugs. The onset of cardiotoxicity may depend on the class, dose, route, and duration of anticancer drug administration and individual risk factors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability. At the same time, new targeted molecules work by interfering with signalling pathways that are important for tumour cells and cardiomyocytes. For example, Bruton tyrosine kinase (BTK) inhibitors interfere with phosphatidylinositol-3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various proteins. Off-target effects of BTK inhibitors are associated with an increased incidence of atrial fibrillation. This review summarises current knowledge about the cardiotoxic effects of targeted therapies used in haematology. Fig. 2, Tab. 3, Ref. 44, on-line full text (Free, PDF) www.cardiology.sk [ABSTRACT FROM AUTHOR]